CELLINK, focused on the development and commercialization of innovative bioprinting technologies and bioinks, announced today that the company will collaborate with AstraZeneca to provide advanced 3D-bioprinted liver organoids for drug discovery purposes in cardiovascular, renal and metabolic diseases.
In tissue engineering, the need for assembly of three-dimensional (3D) tissues is important. 3D-bioprinting has emerged as a useful technology to recapitulate the microenvironment of native tissue, allowing for precise printing of multiple cells into a pre-defined position.
CELLINK has an R&D lab in AstraZeneca’s BioVentureHub in Gothenburg, Sweden. The new collaboration will leverage CELLINK’s innovative and patent-pending bioink, Extra Cellular Matrix and Laminin based bioinks, which enables human cells to grow and function as they would in the human body.
CELLINK collaborates with Lonza to advance complete 3D cell culture workflows